Amedisys (AMED) Tops Q2 EPS by 24c
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Net income attributable to Amedisys, Inc.: 11.44M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Net income attributable to Amedisys, Inc.: 11.44M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.47, $0.24 better than the analyst estimate of $1.23. Revenue for the quarter came in at $557.9 million versus the consensus estimate of $583.12 million.
GUIDANCE:
Amedisys sees FY2022 revenue of $2.29-2.31 billion, versus the consensus of $2.35 billion.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
